Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2006

View Archived Issues

In vivo analysis of beta-lactamase inhibitor NXL-104

Database lock on SIMPADICO trial of Celacade

Crucell licenses STAR technology to Xoma for research

Takeda transfers BASF Takeda Vitamin shares to BASF Japan

Nippon Shinyaku grants Innovive license to NS-187 for CML

TMC-114/ritonavir POWER 2 clinical data and antiviral enhancement with Fuzeon

Preclinical profile of aminocandin presented at ICAAC

pSivida signs new evaluation agreements for new subsidiary

EpiCept completes merger with Maxim Pharmaceuticals

Phase I study to evaluate eniluracil plus 5-FU

AVI BioPharma gets allocation from 2006 defense appropriations act

ZIO-101 to begin phase I/II study in advanced melanoma

Treatment completed in pivotal TRIUMPH study of eculizumab in PNH

Xencor and Roche extend research collaboration

Gabapentin GR shows sustained pain relief without sedation

Study confirms effectiveness of synDNA vaccines in producing immunologic activity

iDESTRIN relieves signs and symptoms of dry eye syndrome in postmenopausal women

Vicuron discloses data on novel azetidine lincosamides

KCP-256: A novel glucose concentration-dependent potentiator of insulin secretion

HPW-RX2 shown to inhibit thrombin and thromboxane formation

Fast track designation for Valortim for anthrax

New approaches for HIV infection treatment disclosed in recent patent literature

New gastric acid antisecretory agents emerge from Altana R&D

Clinical data on brecanavir for HIV infection reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...